| [1] |
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1):1-9.
|
| [2] |
Goel U, Charalampous C, Kapoor P, et al. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma[J]. Blood Cancer J, 2023, 13(1):11.
doi: 10.1038/s41408-023-00785-y
pmid: 36631454
|
| [3] |
Costa LJ, Hungria V, Mohty M, et al. How I treat triple‐class refractory multiple myeloma[J]. Br J Haematol, 2022, 198(2):244-256.
doi: 10.1111/bjh.v198.2
URL
|
| [4] |
Li D, Li X, Zhou WL, et al. Genetically engineered T cells for cancer immunotherapy[J]. Signal Transduct Target Ther, 2019, 4:35.
doi: 10.1038/s41392-019-0070-9
|
| [5] |
Yang Q, Li X, Zhang F, et al. Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: A systematic review and meta-analysis[J]. Int J Med Sci, 2021, 18(8):1786-1797.
doi: 10.7150/ijms.46811
pmid: 33746596
|
| [6] |
Soekojo CY, Chng WJ. Treatment horizon in multiple myeloma[J]. Eur J Haematol, 2022, 109(5):425-440.
doi: 10.1111/ejh.v109.5
URL
|
| [7] |
Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease[J]. Immunol Rev, 2011, 244(1):115-133.
doi: 10.1111/j.1600-065X.2011.01067.x
pmid: 22017435
|
| [8] |
Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma[J]. N Engl J Med, 2019, 380(18):1726-1737.
doi: 10.1056/NEJMoa1817226
URL
|
| [9] |
Manier S, Ingegnere T, Escure G, et al. Current state and next-generation CAR-T cells in multiple myeloma[J]. Blood Rev, 2022, 54:100929.
doi: 10.1016/j.blre.2022.100929
URL
|
| [10] |
Chekol AE, Yibeltal SM, Tadele AF, et al. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma[J]. Front Immunol, 2022, 13:991092.
doi: 10.3389/fimmu.2022.991092
URL
|
| [11] |
Da VM, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma[J]. Nat Med, 2021, 27(4):616-619.
doi: 10.1038/s41591-021-01245-5
pmid: 33619368
|
| [12] |
Wang Y, Cao J, Gu W, et al. Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma[J]. J Clin Oncol, 2022, 40(20):2246-2256.
doi: 10.1200/JCO.21.01676
URL
|
| [13] |
Du J, Jiang H, Dong B, et al. Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)[J]. J Clin Oncol, 2022, 16_suppl(40):8005.
|
| [14] |
Friedman KM, Garrett TE, Evans JW, et al. Effective targeting of multiple B-Cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells[J]. Hum Gene Ther, 2018, 29(5):585-601.
doi: 10.1089/hum.2018.001
pmid: 29641319
|
| [15] |
Munshi NC, Anderson LJ, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma[J]. N Engl J Med, 2021, 384(8):705-716.
doi: 10.1056/NEJMoa2024850
URL
|
| [16] |
Hansen DK, Sidana S, Peres LC, et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: Real-world experience from the myeloma CAR T consortium[J]. J Clin Oncol, 2023, 41(11):2087-2097.
doi: 10.1200/JCO.22.01365
URL
|
| [17] |
Raje NS, Shah N, Jagannath S, et al. Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma[J]. Blood, 2021, 138:548.
doi: 10.1182/blood-2021-146518
URL
|
| [18] |
Zhao WH, Wang BY, Chen LJ, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: A phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)[J]. J Hematol Oncol, 2022, 15(1):86.
doi: 10.1186/s13045-022-01301-8
|
| [19] |
段圆圆, 李子坚. Ciltacabtagene autoleucel——治疗复发难治性多发性骨髓瘤的靶向BCMA CAR-T细胞新型疗法[J]. 中国临床药理学与治疗学, 2022, 27(10):1148-1154.
|
| [20] |
Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up[J]. J Clin Oncol, 2023, 41(6):1265-1274.
doi: 10.1200/JCO.22.00842
URL
|
| [21] |
Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: Phase 1b/2Study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma[J]. Blood, 2021, 138:549.
doi: 10.1182/blood-2021-146060
URL
|
| [22] |
Gagelmann N, Ayuk F, Atanackovic D, et al. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis[J]. Eur J Haematol, 2020, 104(4):318-327.
doi: 10.1111/ejh.13380
pmid: 31883150
|
| [23] |
Mei H, Li C, Jiang H, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma[J]. J Hematol Oncol, 2021, 14(1):161.
doi: 10.1186/s13045-021-01170-7
|
| [24] |
Feng Y, Liu X, Li X, et al. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma[J]. Oncoimmunology, 2021, 10(1):1959102.
doi: 10.1080/2162402X.2021.1959102
URL
|
| [25] |
Mailankody S, Liedtke M, Sidana S, et al. Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma[J]. Blood, 2021, 138:651.
doi: 10.1182/blood-2021-145572
URL
|
| [26] |
Cowan AJ, Pont M, Sather BD, et al. Safety and efficacy of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma[J]. Blood, 2021, 138(Supplement 1):551.
doi: 10.1182/blood-2021-154170
URL
|
| [27] |
Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma[J]. Blood, 2019, 134(19):1585-1597.
doi: 10.1182/blood.2019000050
pmid: 31558469
|
| [28] |
Chen D, Wang X, Chen Z, et al. Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma[J]. Am J Hematol, 2022, 97(12):E478-E481.
doi: 10.1002/ajh.26745
pmid: 36197023
|
)
